Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy

Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.

Neovasc Reducer
Neovasc Reducer • Source: Neovasc

Shockwave Medical plans to acquire Neovasc for up to $147m and help bring the Reducer angina device to the US market.

Under the terms of the agreement, announced on 17 January, Shockwave will pay Neovasc’s shareholders about $100m – $27.25 per...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Strategy

More from Business